MedTrace Logo

Investigating Serotonin Signalling in IBD Patients

NCT01650311 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-11-20

No results posted yet for this study

Summary

Alterations in normal serotonin (5-hydroxytryptamine;5-HT) signaling have been reported in ulcerative colitis (UC) and Crohn's disease (CD). Studies report an increase in enterochromaffin (EC) cell, main source of 5-HT in the gut, numbers in CD and UC patients. Up-regulated expression of mucosal Tryptophan hydroxylase (TPH)-1, catalytic enzyme in 5-HT production, messenger RNA (mRNA) have been found in CD patients in remission who are suffering the irritable bowel syndrome (IBS)-like symptoms. Alterations in normal 5-HT signaling has also been reported in animal models of inflammatory bowel disease (IBD). Thus, the aim of the proposed research project will be to study the alterations in 5-HT signalling accompanying GI inflammatory conditions, such as IBD.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Waliul I Khan, MBBS, PhD. · Dept. of Pathology & Molecular Medicine, McMaster University, Hamilton, Canada.

  • John Marshall, MD, MSc, FRCPC, AGAF. · Department of Medicine, McMaster University, Hamilton, Canada.

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01650311 on ClinicalTrials.gov